title: Adverse affects of paclitaxel and carboplatin combination chemotherapy in epithelial gynecologic cancer.
abstract: OBJECTIVE
  To evaluate the adverse affects of paclitaxel and carboplatin combination chemotherapy.
  
  
  METHODS
  Descriptive cross sectional study
  
  
  METHODS
  Patients with epithelial cancer of the ovary, fallopian tube and peritoneum treated with paclitaxel and carboplatin combination chemotherapy at Chiang Mai University Hospital between August 2003 and August 2004.
  
  
  RESULTS
  Of 224 evaluable cycles in 63 patients treated with paclitaxel (175 mg/m2) and carboplatin (AUC 5), grade 3 and 4 neutropenia occurred in 37.1% or 41.3% of patients. 4.8% of patients experienced febrile neutropenia. Grade 3 and 4 leukopenia occurred in 8.6% of courses and 12.6% of patients. Grade 3 anemia occurred in 5.2% of courses and 9.5% of patients. Grade 3 thrombocytopenia occurred in 2.8% of courses and 9.6% of patients. The nonhematologic adverse affects were rare, however, some adverse events may be potentially life threatening.
  
  
  CONCLUSIONS
  Adverse affects of paclitaxel and carboplatin combination chemotherapy are acceptable and manageable in the majority of patients.
authors.affiliation: Department of Obstetrics and Gynecology, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand. kiet_ji@hotmail.com
authors.forename: Chumnan
authors.initials: C
authors.lastname: Kietpeerakool
authors.forename: Prapaporn
authors.initials: P
authors.lastname: Suprasert
authors.forename: Jatupol
authors.initials: J
authors.lastname: Srisomboon
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects*; D016190:Carboplatin / Q000008:administration & dosage / Q000009:adverse effects; D003430:Cross-Sectional Studies; D005185:Fallopian Tube Neoplasms / Q000188:drug therapy; D005260:Female; D005833:Genital Neoplasms, Female / Q000188:drug therapy*; D006402:Hematologic Diseases / Q000139:chemically induced; D006801:Humans; D008875:Middle Aged; D009375:Neoplasms, Glandular and Epithelial / Q000188:drug therapy*; D010051:Ovarian Neoplasms / Q000188:drug therapy; D017239:Paclitaxel / Q000008:administration & dosage / Q000009:adverse effects; D010534:Peritoneal Neoplasms / Q000188:drug therapy; D016896:Treatment Outcome
chemical_list: D016190:Carboplatin; D017239:Paclitaxel